Title: Application of ultrasound contrast agents in high-intensive focused ultrasound for clinical treatment of middle-late stage prostate cancer
Abstract: 【Objective】To study ultrasound contrast agents in high-intensive focused ultrasound for middle-late stage prostate cancer. 【Methods】10 cases of middle-late stage prostate cancer were treated with the Sonablat-500TM therapeutic system. The prostates were observed by transrectal color doppler flow imaging(CDFI) and ultrasound contrast pre-and post-treatment. 60 patients after treatment were followed up 12 months.【Result】The mean IPSS symptomscore was improved. QQL index became lower, while Qmax improved, PVR decreased(P 0.01) and volume of prostate reduced(P 0.05) significantly. The systolic velocity(VS), diastolic velocity(VD), resistent index(RI), blood vessel inside diameter(D), accelerate index(AI), were significantly decreased after treatment(P 0.01).【Conclusion】HIFU for prostate cancer is safe and effective method, ultrasonic contrast can accurately show that HIFU prostate cancer treatment of the ablation range and degree, and ultrasound contrast agents can play the role of the enhancing transrectal color doppler ultrasound for its curative effect evaluation with an intuitive, accurate method.
Publication Year: 2013
Publication Date: 2013-01-01
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot